Non-Hodgkin Lymphoma

The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy, based on findings from a single-arm phase II study.

Danelle James, MD, discusses the updated RESONATE-2 data presented at the ASH Annual Meeting and the next steps with ibrutinib in CLL.

The fields of mantle cell lymphoma and diffuse large B-cell lymphoma had a handful of updates presented during the 2016 ASH Annual Meeting.

KTE-C19, an investigational CAR T-cell therapy, recently demonstrated positive results for patients with chemorefractory aggressive non-Hodgkin lymphoma.

The regimen of rituximab plus CHOP chemotherapy has been the standard of care for patients with previously untreated diffuse large B-cell lymphoma for several years, and it appears it will remain that way for now, despite recent research to find novel alternatives.

Changes are underway in the field of hematologic malignancies, as the World Health Organization is publishing a revised classification of tumors of hematopoietic and lymphoid tissues—slated to be released in early 2017.